Evaluation of Local and Systemic Reactogenicity Following Serial Administration of ADVAX, a Clade C DNA Vaccine, ADVAX e/g + ADVAX p/n-t, by Ichor TriGrid in Vivo Electroporation to HIV-Uninfected, Healthy Volunteers

Trial Profile

Evaluation of Local and Systemic Reactogenicity Following Serial Administration of ADVAX, a Clade C DNA Vaccine, ADVAX e/g + ADVAX p/n-t, by Ichor TriGrid in Vivo Electroporation to HIV-Uninfected, Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 07 May 2011

At a glance

  • Drugs ADVAX (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms ADVAX-EP
  • Most Recent Events

    • 07 May 2011 NCT reports actual end date is Apr 2011.
    • 01 Dec 2009 Positive results presented at the AIDS Vaccine Conference. Additional analyses are underway.
    • 01 Dec 2009 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top